National Survey on Gastroesophageal Reflux Disease (GERD) Patients (LINEA)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00695838
First received: June 10, 2008
Last updated: August 4, 2009
Last verified: August 2009

June 10, 2008
August 4, 2009
January 2008
Not Provided
Waist circumference [ Time Frame: Once ]
Same as current
Complete list of historical versions of study NCT00695838 on ClinicalTrials.gov Archive Site
  • Frequency of GERD symptoms [ Time Frame: Once ]
  • GERD impact scale [ Time Frame: Once ]
Same as current
Not Provided
Not Provided
 
National Survey on Gastroesophageal Reflux Disease (GERD) Patients
Evaluation of the Impact of Abdominal Fat on GERD Severity and GERD Frequency in General Practice

The purpose of this observational study is to assess the impact of abdominal fat on severity and frequency of GERD symptoms .

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

First three consecutive patients with GERD symptoms seen by GP

GERD
Not Provided
1
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5084
December 2008
Not Provided

Inclusion Criteria:

  • Male or female > or = 18 years old
  • Patient with symptomatic GERD
  • Without PPI or H2 antagonist treatment during the 3 previous months
  • Agree to take part in this study

Exclusion Criteria:

  • Pregnant women
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00695838
NIS-GFR-DUM-2007/3
No
Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
AstraZeneca
Not Provided
Study Director: Alain Castaigne, Medical Director AstraZeneca
AstraZeneca
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP